These incretin mimetic drugs may be linked with the increased danger of pancreatitis and pancreatic cancer.
If you suffer from type 2 diabetes and have been prescribed Januvia®, Victoza®, Janumet® or Byetta® you may be three times more likely to acquire pancreatic cancer. The prestigious Journal of the American Medical Association April 2013 publication reflected results of a study indicating the use of Byetta® or Januvia® by type 2 diabetic adults was “associated with significantly increased odds of acute pancreatitis.” Pancreatic cancer may result from chronic pancreatitis.
Gastroenterology, a medical journal, published 2011 study results indicating diabetics taking Byetta® or Januvia® were six times more likely to report pancreatitis as opposed to diabetics using other drug treatments. Pancreatic cancer reports by diabetics using Byetta® were 2.9 times more likely than those using other drugs while diabetics using Januvia® were 2.7 times more likely to report pancreatic cancer than those using other drugs.
Januvia® (sitagliptin) is a once a day pill prescribed for type 2 diabetics associated with pancreatitis and pancreatic cancer.
Victoza® (liraglutide) is a once daily injection used in treatment of type 2 diabetes that has been associated with the danger of pancreatitis and also medullary thyroid cancer.
Janumet® (sitagliptin and metformin) is a tablet prescribed for type 2 diabetes associated with pancreatitis and pancreatic cancer.
Byetta® (exenatide) is an injectable prescription for type 2 diabetics associated with pancreatitis and pancreatic cancer.